Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ENZY's Cash-to-Debt is ranked higher than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ENZY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ENZY's Equity-to-Asset is ranked higher than
91% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ENZY: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.92 Max: 0.93
Current: 0.92
0.67
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked higher than
69% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 30.19 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 13.31
Beneish M-Score: -2.75
WACC vs ROIC
10.85%
-8.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -15.87
ENZY's Operating Margin % is ranked higher than
66% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ENZY: -15.87 )
Ranked among companies with meaningful Operating Margin % only.
ENZY' s Operating Margin % Range Over the Past 10 Years
Min: -15.87  Med: 13.15 Max: 18.1
Current: -15.87
-15.87
18.1
Net Margin % -14.52
ENZY's Net Margin % is ranked higher than
65% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ENZY: -14.52 )
Ranked among companies with meaningful Net Margin % only.
ENZY' s Net Margin % Range Over the Past 10 Years
Min: -14.52  Med: 12.95 Max: 17.54
Current: -14.52
-14.52
17.54
ROE % -4.95
ENZY's ROE % is ranked higher than
73% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ENZY: -4.95 )
Ranked among companies with meaningful ROE % only.
ENZY' s ROE % Range Over the Past 10 Years
Min: -4.95  Med: 4.12 Max: 6.52
Current: -4.95
-4.95
6.52
ROA % -4.55
ENZY's ROA % is ranked higher than
73% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ENZY: -4.55 )
Ranked among companies with meaningful ROA % only.
ENZY' s ROA % Range Over the Past 10 Years
Min: -4.55  Med: 5.18 Max: 12.16
Current: -4.55
-4.55
12.16
ROC (Joel Greenblatt) % -11.41
ENZY's ROC (Joel Greenblatt) % is ranked higher than
72% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ENZY: -11.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.41  Med: 12.6 Max: 28.12
Current: -11.41
-11.41
28.12
3-Year Revenue Growth Rate -33.10
ENZY's 3-Year Revenue Growth Rate is ranked lower than
79% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ENZY: -33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -33.1 Max: -5
Current: -33.1
3-Year EBITDA Growth Rate -88.80
ENZY's 3-Year EBITDA Growth Rate is ranked lower than
99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ENZY: -88.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ENZY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88.8 Max: -4.4
Current: -88.8
GuruFocus has detected 3 Warning Signs with Enzymotec Ltd $ENZY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ENZY Guru Trades in Q3 2016

Julian Robertson 677,548 sh (+17.34%)
Jim Simons 258,300 sh (+7.18%)
John Paulson 4,205,980 sh (-0.43%)
» More
Q4 2016

ENZY Guru Trades in Q4 2016

Jim Simons 290,000 sh (+12.27%)
John Paulson 4,205,980 sh (unchged)
Julian Robertson 677,548 sh (unchged)
» More
Q1 2017

ENZY Guru Trades in Q1 2017

John Paulson 4,205,980 sh (unchged)
Julian Robertson 677,548 sh (unchged)
Jim Simons 288,700 sh (-0.45%)
» More
Q2 2017

ENZY Guru Trades in Q2 2017

Jim Simons 299,000 sh (+3.57%)
Julian Robertson 677,548 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-08-23 Reduce -50.00%0.31%Premium Member Access $11 $ 11.383%2,102,990
John Paulson 2016-09-30 Reduce -0.43%$6.85 - $9.26 $ 11.3842%4,205,980
Julian Robertson 2016-09-30 Add 17.34%0.17%$6.85 - $9.26 $ 11.3842%677,548
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:XTAE:NTEC, NAS:FOMX, XTAE:KMDA, NAS:CGEN, XTAE:RDHL, NAS:VBLT, NAS:MDWD, NAS:PSTI, NAS:ORMP, XTAE:CBI, XTAE:EVGN, NAS:BLRX, NAS:GLMD, NAS:URGN, AMEX:PLX, XTAE:APOP, OTCPK:TOMDF, XTAE:BVXV, NAS:ADHD, XTAE:CFBI » details
Traded in other countries:EZ4.Germany,
Headquarter Location:Israel
Enzymotec Ltd is a nutritional ingredients and medical foods company. The Company develops, manufactures, markets and sells bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies.

Ratios

vs
industry
vs
history
PB Ratio 1.94
ENZY's PB Ratio is ranked higher than
87% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ENZY: 1.94 )
Ranked among companies with meaningful PB Ratio only.
ENZY' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.47 Max: 11.01
Current: 1.94
0.91
11.01
PS Ratio 5.55
ENZY's PS Ratio is ranked higher than
75% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ENZY: 5.55 )
Ranked among companies with meaningful PS Ratio only.
ENZY' s PS Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.73 Max: 5.84
Current: 5.55
1.41
5.84
Price-to-Operating-Cash-Flow 97.27
ENZY's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. ENZY: 97.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.04  Med: 28.2 Max: 605.88
Current: 97.27
11.04
605.88
EV-to-EBIT -31.78
ENZY's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ENZY: -31.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.5  Med: 23.5 Max: 55.1
Current: -31.78
-67.5
55.1
EV-to-EBITDA -54.03
ENZY's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ENZY: -54.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.1  Med: 18.6 Max: 4653.8
Current: -54.03
-118.1
4653.8
EV-to-Revenue 4.74
ENZY's EV-to-Revenue is ranked higher than
81% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ENZY: 4.74 )
Ranked among companies with meaningful EV-to-Revenue only.
ENZY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 3.3 Max: 10
Current: 4.74
1.3
10
Current Ratio 6.84
ENZY's Current Ratio is ranked higher than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ENZY: 6.84 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 1.78  Med: 7.4 Max: 9.06
Current: 6.84
1.78
9.06
Quick Ratio 4.72
ENZY's Quick Ratio is ranked higher than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ENZY: 4.72 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 5.4 Max: 7.31
Current: 4.72
1.27
7.31
Days Inventory 487.18
ENZY's Days Inventory is ranked lower than
97% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ENZY: 487.18 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 251.79 Max: 496.17
Current: 487.18
121.07
496.17
Days Sales Outstanding 89.77
ENZY's Days Sales Outstanding is ranked lower than
64% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ENZY: 89.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.82  Med: 108.17 Max: 120.92
Current: 89.77
76.82
120.92
Days Payable 86.76
ENZY's Days Payable is ranked higher than
71% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ENZY: 86.76 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 86.76  Med: 106.61 Max: 145.45
Current: 86.76
86.76
145.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
ENZY's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ENZY: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.8  Med: -2 Max: 0
Current: -2
-14.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.35
ENZY's Price-to-Net-Cash is ranked higher than
59% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ENZY: 10.35 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.11  Med: 7.05 Max: 14.2
Current: 10.35
5.11
14.2
Price-to-Net-Current-Asset-Value 4.21
ENZY's Price-to-Net-Current-Asset-Value is ranked higher than
82% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ENZY: 4.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.12  Med: 2.88 Max: 14.91
Current: 4.21
2.12
14.91
Price-to-Tangible-Book 1.97
ENZY's Price-to-Tangible-Book is ranked higher than
90% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ENZY: 1.97 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 1.46 Max: 6.82
Current: 1.97
1.1
6.82
Price-to-Median-PS-Value 1.49
ENZY's Price-to-Median-PS-Value is ranked lower than
62% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ENZY: 1.49 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 1.01 Max: 1.52
Current: 1.49
0.37
1.52
Earnings Yield (Greenblatt) % -3.14
ENZY's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ENZY: -3.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.9  Med: 3.45 Max: 13.9
Current: -3.14
-5.9
13.9

More Statistics

Revenue (TTM) (Mil) $47.01
EPS (TTM) $ -0.30
Beta1.47
Short Percentage of Float0.85%
52-Week Range $5.20 - 12.35
Shares Outstanding (Mil)22.94

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.50
EPS without NRI ($) 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Aug 30 2017 
Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd. Aug 28 2017 
Frutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% St Aug 24 2017 
Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer Jul 28 2017 
Enzymotec to Report Second Quarter 2017 Financial Results Jul 26 2017 
Enzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold Jun 06 2017 
Enzymotec Ltd. to Present at the Jefferies 2017 Global Healthcare Conference May 25 2017 
Enzymotec to Report First Quarter 2017 Financial Results May 03 2017 
VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods May 02 2017 
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017 

More From Other Websites
Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union... Aug 30 2017
Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd. Aug 28 2017
Corporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives Aug 28 2017
Frutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% Stake... Aug 24 2017
Enzymotec reports 2Q loss Aug 16 2017
Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results Aug 16 2017
Investor Network: Enzymotec Ltd. to Host Earnings Call Aug 16 2017
Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer Jul 28 2017
Enzymotec to Report Second Quarter 2017 Financial Results Jul 26 2017
Enzymotec Chief Financial Officer to Step Down Jun 28 2017
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
Weakness Seen in Enzymotec (ENZY) Estimates: Should You Stay Away? Jun 13 2017
Enzymotec misses 1Q profit forecasts May 17 2017
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q4, 2016 By the Numbers : April 3, 2017 Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}